Stockscreener 앱 받기
14.28
2.33%
-0.34
시간 외 거래:
14.50
0.22
+1.54%
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking - Simply Wall St
Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2024 Earnings Call Transcript - MSN
Arcus Biosciences to Present at Evercore and Citi Healthcare Conferences in December | RCUS Stock News - StockTitan
Arcus Biosciences' SWOT analysis: biotech stock faces pivotal data releases - Investing.com
Arcus Biosciences' SWOT analysis: biotech stock faces pivotal data releases By Investing.com - Investing.com Australia
FMR LLC Bolsters Stake in Arcus Biosciences Inc - GuruFocus.com
Arcus Biosciences Awards Key Equity Grants to New Hires at $17.85 Per Share | RCUS Stock News - StockTitan
GSA Capital Partners LLP Raises Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
FY2024 Earnings Forecast for RCUS Issued By HC Wainwright - MarketBeat
Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report - Yahoo Finance
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Arcus Biosciences (NYSE:RCUS) Posts Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: S - GuruFocus.com
Analysts Set Arcus Biosciences, Inc. (NYSE:RCUS) Price Target at $33.67 - MarketBeat
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of “Buy” from Analysts - Defense World
Arcus Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arcus Biosciences Surges: 34% Cancer Trial Success, AstraZeneca Deal Boosts Q3 | RCUS Stock News - StockTitan
Arcus Biosciences (NYSE:RCUS) Receives "Neutral" Rating from HC Wainwright - MarketBeat
Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts - Benzinga
Arcus up 4% following Merck Welireg kidney cancer data - MSN
Arcus says Gilead-partnered cancer therapy cut death risk by 36% - Seeking Alpha
Arcus reports improved survival with cancer drug combo - Investing.com
Arcus Biosciences (RCUS) Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10 - StreetInsider.com
Arcus Bio's Cancer Drug Combo Cuts Death Risk by 36%, Doubles Survival Time in Lung Cancer Trial | RCUS Stock News - StockTitan
What To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 Earnings - GuruFocus.com
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
(RCUS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
This Arcus Biosciences Insider Reduced Their Stake By 27% - Simply Wall St
Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for - MSN
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting - StockTitan
Arcus Biosciences (RCUS) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Arcus Biosciences: Advancing On Several Fronts (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences (NYSE:RCUS) Trading Down 5.3%Should You Sell? - MarketBeat
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $29.00 at Barclays - MarketBeat
Arcus Biosciences' SWOT analysis: stock outlook hinges on clinical trials - Investing.com India
Arcus Begins Differentiating Its HIF-2a inhibitor Versus Merck’s Welireg - Scrip
Arcus Biosciences Announces New Employment Inducement Grants - StockTitan
Health Care Down Amid Mixed Drug Developments -- Health Care Roundup - Marketscreener.com
Citi raises Arcus Biosciences target to $46, maintains buy By Investing.com - Investing.com Canada
Arcus Biosciences (RCUS) PT Raised to $46 at Citi - StreetInsider.com
Neutral stance on Arcus Biosciences maintained by BofA - Investing.com Canada
BofA Securities Reiterates Neutral Rating on Arcus Biosciences (RCUS) - StreetInsider.com
Arcus Biosciences (NYSE:RCUS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Arcus Biosciences' SWOT analysis: stock outlook hinges on clinical trials By Investing.com - Investing.com South Africa
Arcus Biosciences Inc (NYSE: RCUS) Could Slash -153.89% Soon - Stocks Register
Arcus Biosciences Shares Rise After Kidney Cancer Drug Shows Promise in Early-Stage Trial - MarketWatch
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer - StockTitan
(RCUS) Technical Pivots with Risk Controls - Stock Traders Daily
Arcus started at neutral by H.C. Wainwright, upcoming data cited - MSN
Research Analysts Issue Forecasts for RCUS Q3 Earnings - MarketBeat
Exchange Traded Concepts LLC Has $152,000 Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
0.93%
3.55%
자본화:
|
볼륨(24시간):